06.27.2024 

Celsius Therapeutics (President and CEO: Tariq Kassum, MD; Headquarters: Cambridge, USA), has been acquired by AbbVie, a global leader in biopharmaceuticals. Under the terms of the agreement, AbbVie has acquired all outstanding equity of Celsius Therapeutics for a total of $250 million in cash, subject to customary adjustments. 

View the original press release here: https://news.abbvie.com/2024-06-27-AbbVie-Acquires-Celsius-Therapeutics

About Celsius Therapeutics:

Celsius Therapeutics is a clinical-stage biotechnology company developing novel precision medicines in inflammatory disease by harnessing the power of single cell RNA sequencing and human biology at scale. The company’s first therapeutic candidate is an anti-TREM1 antibody for the treatment of IBD. Celsius is based in Cambridge, Mass. For more information, please visit https://celsiustx.com, or follow us on LinkedIn or Twitter.

 

About AbbVie:

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

 

About Fast Track Initiative:

Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.

Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/

 

Media Contact:

For press inquiries or investor inquiries, please email:  message.us@fasttrackinitiative.com